Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial

Reszka, 2003, Mechanism of action of bisphosphonates, Curr Osteoporos Rep, 1, 45, 10.1007/s11914-003-0008-5

Delmas, 2008, Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases, J Clin Densitom, 11, 325, 10.1016/j.jocd.2008.02.002

Dempster, 2012, Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial, J Clin Endocrinol Metab, 97, 2799, 10.1210/jc.2012-1262

Compston, 2012, The use of combination therapy in the treatment of postmenopausal osteoporosis, Endocrine, 41, 11, 10.1007/s12020-011-9554-2

Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975

Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis, J Bone Miner Res, 26, 503, 10.1002/jbmr.238

Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med, 349, 1216, 10.1056/NEJMoa035725

Finkelstein, 2010, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis, J Clin Endocrinol Metab, 95, 1838, 10.1210/jc.2009-1703

Deal, 2005, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial, J Bone Miner Res, 20, 1905, 10.1359/JBMR.050714

Tsai, 2013, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial, Lancet, 382, 50, 10.1016/S0140-6736(13)60856-9

Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904

Black, 2001, An assessment tool for predicting fracture risk in postmenopausal women, Osteoporos Int, 12, 519, 10.1007/s001980170072

Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med, 356, 1809, 10.1056/NEJMoa067312

Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493

Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201

McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group, N Engl J Med, 344, 333, 10.1056/NEJM200102013440503

Chesnut, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, 1241, 10.1359/JBMR.040325

Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA, 282, 637, 10.1001/jama.282.7.637

Kostenuik, 2001, OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats, Endocrinology, 142, 4295, 10.1210/endo.142.10.8437

Samadfam, 2007, Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice, J Bone Miner Res, 22, 55, 10.1359/jbmr.060915

Muschitz, 2013, Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density, J Bone Miner Res, 28, 196, 10.1002/jbmr.1716

Kurland, 2000, Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers, J Clin Endocrinol Metab, 85, 3069

Lindsay, 1997, Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis, Lancet, 350, 550, 10.1016/S0140-6736(97)02342-8

Chen, 2006, Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis, J Bone Miner Res, 21, 1785, 10.1359/jbmr.060802

Austin, 2012, Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, J Bone Miner Res, 27, 687, 10.1002/jbmr.1472